Table of Contents
Lung Cancer International
Volume 2013, Article ID 436409, 7 pages
http://dx.doi.org/10.1155/2013/436409
Review Article

Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC

1Eastern Virginia Medical School, 700 West Olney Road Norfolk, Norfolk, VA 23507, USA
2Virginia Oncology Associates, Eastern Virginia Medical School, 5900 Lake Wright Drive Norfolk, Norfolk, VA 23502, USA

Received 28 July 2013; Accepted 30 November 2013

Academic Editor: Natasha B. Leighl

Copyright © 2013 Ali A. Bukhari and Ranjit K. Goudar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Howlader, A. Noone, M. Krapcho et al., “SEER cancer statistics review,” 1975–2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, based on November 2011 SEER data submission, posted to the SEER web site, April 2012 http://seer.cancer.gov/csr/1975_2009_pops09/.
  3. J. H. Schiller, D. Harrington, C. P. Belani et al., “Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer,” The New England Journal of Medicine, vol. 346, no. 2, pp. 92–98, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. G. V. Scagliotti, P. Parikh, J. Von Pawel et al., “Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3543–3551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Hanna, F. A. Shepherd, F. V. Fossella et al., “Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1589–1597, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. L. G. Paz-Ares, S. Altug, A. T. Vaury, J. C. Jaime, F. Russo, and C. Visseren-Grul, “Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer,” BMC Cancer, vol. 10, article 85, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Solomon and P. A. Bunn Jr., “Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent,” Future oncology, vol. 1, no. 6, pp. 733–746, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Joerger, A. Omlin, T. Cerny, and M. Früh, “The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action,” Current Drug Targets, vol. 11, no. 1, pp. 37–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Chattopadhyay, R. G. Moran, and I. D. Goldman, “Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications,” Molecular Cancer Therapeutics, vol. 6, no. 2, pp. 404–417, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. G. V. Scagliotti, C. Kortsik, G. G. Dark et al., “Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial,” Clinical Cancer Research, vol. 11, no. 2 I, pp. 690–696, 2005. View at Google Scholar · View at Scopus
  11. J. Sigmond, H. H. J. Backus, D. Wouters, O. H. Temmink, G. Jansen, and G. J. Peters, “Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression,” Biochemical Pharmacology, vol. 66, no. 3, pp. 431–438, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Takezawa, I. Okamoto, W. Okamoto et al., “Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer,” British Journal of Cancer, vol. 104, no. 10, pp. 1594–1601, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Ceppi, M. Volante, S. Saviozzi et al., “Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase,” Cancer, vol. 107, no. 7, pp. 1589–1596, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Ishihama, M. Chida, O. Araki et al., “Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung,” Japanese Journal of Clinical Oncology, vol. 39, no. 1, pp. 33–36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. G. R. Simon, S. Sharma, A. Cantor, P. Smith, and G. Bepler, “ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer,” Chest, vol. 127, no. 3, pp. 978–983, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. K. A. Olaussen, A. Dunant, P. Fouret et al., “DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy,” The New England Journal of Medicine, vol. 355, no. 10, pp. 983–991, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. G. Bepler, S. Sharma, A. Cantor et al., “RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1878–1885, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler, “DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer,” The New England Journal of Medicine, vol. 356, no. 8, pp. 800–808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Bepler, I. Kusmartseva, S. Sharma et al., “RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4731–4737, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Bepler, K. A. Olaussen, A.-L. Vataire et al., “ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis,” American Journal of Pathology, vol. 178, no. 1, pp. 69–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Reynolds, C. Obasaju, M. J. Schell et al., “Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5808–5815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Besse, K. A. Olaussen, and J. C. Soria, “ERCC1 and RRM1: ready for prime time?” Journal of Clinical Oncology, vol. 31, pp. 1050–1060, 2013. View at Publisher · View at Google Scholar
  23. L. Friboulet, K. A. Olaussen, J. P. Pignon et al., “ERCC1 isoform expression and DNA repair in non-small-cell lung cancer,” The New England Journal of Medicine, vol. 368, pp. 1101–1110, 2013. View at Publisher · View at Google Scholar
  24. H. Hashimoto, Y. Ozeki, M. Sato et al., “Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung,” Cancer, vol. 106, no. 7, pp. 1595–1601, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Zheng, X. Li, M. J. Schell et al., “Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer,” Cancer, vol. 112, no. 12, pp. 2765–2773, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. Y. Shintani, M. Ohta, H. Hirabayashi et al., “New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction,” International Journal of Cancer, vol. 104, no. 6, pp. 790–795, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. R. K. Kelley, C. Atreya, A. P. Venook, and P. G. Febbo, “Predictive biomarkers in advance of a companion drug: ahead of their time?” JNCCN Journal of the National Comprehensive Cancer Network, vol. 10, no. 3, pp. 303–309, 2012. View at Google Scholar · View at Scopus
  28. C.-Y. Chen, Y.-L. Chang, J.-Y. Shih et al., “Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed,” Lung Cancer, vol. 74, no. 1, pp. 132–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. D. C. Christoph, B. R. Asuncion, B. Hassan et al., “Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed,” Journal of Thoracic Oncology, vol. 8, no. 1, pp. 19–30, 2013. View at Publisher · View at Google Scholar
  30. G. V. Scagliotti, C. Kaiser, B. Biesma et al., “Correlations of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): C6-01,” Journal of Thoracic Oncology, no. 2, p. S375, 2007. View at Google Scholar
  31. A. Silva and J. Cole, “Thymidylate synthase expression and pemetrexed therapy in NSCLC,” Journal of Clinical Oncology, vol. 29, 2011. View at Google Scholar
  32. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Google Scholar · View at Scopus
  33. S. Igawa, S. Ryuge, M. Wada et al., “Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression,” Chemotherapy, vol. 58, pp. 313–320, 2012. View at Publisher · View at Google Scholar
  34. J.-M. Sun, J. Han, J. S. Ahn, K. Park, and M.-J. Ahn, “Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy,” Journal of Thoracic Oncology, vol. 6, no. 8, pp. 1392–1399, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. H. Chang, J. S. Ahn, J. Lee et al., “The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer,” Lung Cancer, vol. 69, no. 3, pp. 323–329, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Shimizu, Y. Nakanishi, Y. Nakagawa et al., “Association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer,” Anticancer Research, vol. 32, pp. 4589–4596, 2012. View at Google Scholar
  37. W. J. Li, H. Jiang, X. J. Fang et al., “Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy,” Oncology letters, vol. 5, no. 4, pp. 1165–1170, 2013. View at Google Scholar
  38. E. F. Smit, S. A. Burgers, B. Biesma et al., “Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2038–2045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Bepler, K. E. Sommers, A. Cantor et al., “Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 3, no. 10, pp. 1112–1118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. C. Nicolson, D. A. Fennell, D. Ferry et al., “Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial,” Journal of Thoracic Oncology, vol. 8, no. 7, pp. 930–939, 2013. View at Publisher · View at Google Scholar
  41. G. Scagliotti, T. Brodowicz, F. A. Shepherd et al., “Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 6, no. 1, pp. 64–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. M. K. Maus, P. C. Mack, S. H. Astrow et al., “Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy,” Journal of Thoracic Oncology, vol. 8, no. 5, pp. 582–586, 2013. View at Publisher · View at Google Scholar
  43. G. Chen, T. G. Gharib, C.-C. Huang et al., “Discordant protein and mRNA expression in lung adenocarcinomas,” Molecular & Cellular Proteomics, vol. 1, no. 4, pp. 304–313, 2002. View at Google Scholar · View at Scopus
  44. M. Nicolson, K. Kerr, R. Shah et al., “Correlation between thymidylate synthetase (TS) expression and progression-free survival (PFS) in patients receiving pemetrexed (pem) for advanced NSCLC: a prospective study,” Journal of Clinical Oncology, vol. 30, 2012. View at Google Scholar
  45. P. G. Johnston, H.-J. Lenz, C. G. Leichman et al., “Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors,” Cancer Research, vol. 55, no. 7, pp. 1407–1412, 1995. View at Google Scholar · View at Scopus
  46. M. Ahn, “A randomized phase II study comparingp pemetrexed plus cisplatin with gemcitabine plus cisplatin according to thymidylate synthase expression in non-squamous non-small cell lung cancer,” Personal Communication. In press.
  47. Y. Liu, T. J. Yin, R. Zhou, S. Zhou, L. Fan, and R. G. Zhang, “Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis,” Cancer Chemotherapy and Pharmacology, vol. 72, pp. 1125–1132, 2013. View at Google Scholar
  48. D. B. Longley and P. G. Johnston, “Molecular mechanisms of drug resistance,” Journal of Pathology, vol. 205, no. 2, pp. 275–292, 2005. View at Publisher · View at Google Scholar · View at Scopus